+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Market Spotlight: Hypogonadism

  • ID: 4775116
  • Report
  • February 2021
  • Region: Global
  • 30 Pages
  • Pharma Intelligence
This Market Spotlight report covers the Hypogonadism market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, key upcoming and regulatory events, probability of success, patent information, epidemiology, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The approved drugs in the hypogonadism space target androgen receptors, estrogen receptor alpha, and estrogen receptor beta. These are commonly administered via the transdermal route, with a smaller number of products being available in oral, intramuscular, intranasal, sublingual/oral transmucosal, subcutaneous, and topical formulations.
  • The largest proportion of industry-sponsored drugs in active clinical development for hypogonadism are in Phase II, with only one drug in Phase III and one in the NDA/BLA phase.
  • Therapies in development for hypogonadism focus on targets such as androgen receptors, estrogen receptor alpha, estrogen receptor beta, and aromatase. These pipeline drugs are administered via the oral route.
  • Expected PDUFA dates for Tlando and Kyzatrex are the only high-impact upcoming events for drugs in hypogonadism space. The overall likelihood of approval of a Phase I endocrine-other asset is 16.4%, and the average probability a drug advances from Phase III is 65.9%. Drugs, on average, take 10.0 years from Phase I to approval, compared to 9.6 years in the overall endocrine space.
  • There are almost equal proportions of clinical trials for hypogonadism across Phase I–IV, with 51% in Phase I–II, and 49% in Phase III–IV.
  • The US has a substantial lead in the number of hypogonadism clinical trials globally. The UK leads the major European markets, while India has the top spot in Asia.
  • Clinical trial activity in the hypogonadism space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for hypogonadism, with eight trials.
  • AbbVie leads industry sponsors with the highest overall number of clinical trials for hypogonadism, followed by GlaxoSmithKline.

Table of Contents

OVERVIEWKEY TAKEAWAYS
DISEASE BACKGROUND
  • Subtypes

TREATMENT
  • Treatment of hypogonadism in females
  • Treatment of hypogonadism in males

EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGSKEY UPCOMING EVENTS
KEY REGULATORY EVENTS
  • Reanalysis Of Existing Data Supports Lipocine Tlando Resubmission

PROBABILITY OF SUCCESSREVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY
  • Prescription information

APPENDIX
LIST OF FIGURES
Figure 1: Overview of pipeline drugs for hypogonadism in the US
Figure 2: Pipeline drugs for hypogonadism, by company
Figure 3: Pipeline drugs for hypogonadism, by drug type
Figure 4: Pipeline drugs for hypogonadism, by classification
Figure 5: Key upcoming events in hypogonadism
Figure 6: Probability of success in the endocrine-other pipeline
Figure 7: Clinical trials in hypogonadism
Figure 8: Top 10 drugs for clinical trials in hypogonadism
Figure 9: Top 10 companies for clinical trials in hypogonadism
Figure 10: Trial locations in hypogonadism
Figure 11: Hypogonadism trials status
Figure 12: Hypogonadism trials sponsors, by phase
LIST OF TABLES
Table 1: Marketed drugs for hypogonadism
Table 2: Pipeline drugs for hypogonadism in the US
Table 3: Historical global sales, by drug ($m), 2015–19
Table 4: Forecasted global sales, by drug ($m), 2021–25